Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463518 | 1.00 | PKM (0.51) | PKMALDH1A1STAT3RIPK1CYP2D6 | |
| SCHEMBL1463520 | 1.00 | PKM (0.51) | PKMALDH1A1STAT3RIPK1CYP2D6 | |
| SCHEMBL4655851 | 0.87 | LMNA (0.44) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL2545829 | 0.85 | PKM (0.53) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL7840144 | 0.85 | ALDH1A1 (0.43) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL4920359 | 0.85 | PKM (0.53) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL1206501 | 0.85 | PKM (0.53) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL6005431 | 0.85 | PKM (0.43) | PKMALDH1A1STAT3CYP2D6MAPK1 | |
| SCHEMBL18092987 | 0.84 | ALDH1A1 (0.45) | PKMALDH1A1STAT3VDRLMNA | |
| SCHEMBL18092988 | 0.84 | ALDH1A1 (0.45) | PKMALDH1A1STAT3VDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598160-B2 | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2254872-A2 | CYCLOALKYL LACTAME DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009102460-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102460-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | PKM 1930/4885ALDH1A1 115/4885STAT3 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.